Frederic Moll Acquires 501,253 Shares of SS Innovations International (NASDAQ:SSII) Stock

March 11, 2026 by InsiderTrades.com

Key Points

Vice‑Chair Dr. Frederic Moll bought 501,253 shares at an average $3.99 (~$2.0M) on March 6, increasing his stake to 10,775,485 shares (a 4.88% rise), a substantial insider purchase signaling management confidence.
SS Innovations completed a private placement raising approximately $18.6 million (5.77M shares) to fund global expansion and working capital, but the issuance and related unregistered securities/warrants create dilution and potential downward pressure on the stock.
The company reported Q4/FY2025 revenue growth and increased SSi Mantra installations, yet it still has negative margins and ROE, faces an FDA 510(k) review expected mid‑2026 (execution risk), and analysts currently maintain a “Sell” consensus.

SS Innovations International, Inc. (NASDAQ:SSII - Get Free Report) Director Frederic Moll bought 501,253 shares of the firm's stock in a transaction dated Friday, March 6th. The shares were acquired at an average cost of $3.99 per share, with a total value of $1,999,999.47. Following the completion of the transaction, the director owned 10,775,485 shares of the company's stock, valued at $42,994,185.15. This represents a 4.88% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link.

SS Innovations International Stock Performance

Shares of NASDAQ SSII opened at $4.42 on Wednesday. The stock has a market cap of $859.07 million and a price-to-earnings ratio of -88.40. SS Innovations International, Inc. has a fifty-two week low of $3.02 and a fifty-two week high of $22.42. The firm's 50-day simple moving average is $4.82 and its 200 day simple moving average is $6.05.

SS Innovations International (NASDAQ:SSII - Get Free Report) last announced its quarterly earnings results on Tuesday, January 13th. The company reported $0.04 earnings per share (EPS) for the quarter. SS Innovations International had a negative return on equity of 34.13% and a negative net margin of 32.10%.The business had revenue of $14.53 million during the quarter.

Key Stories Impacting SS Innovations International

Here are the key news stories impacting SS Innovations International this week:

Positive Sentiment: CEO Srivastava purchased 498,753 shares (~$2.0M) at ~$4.01, a small increase to his very large holding — insider buying often signals management confidence. SEC filing: Srivastava purchase
Positive Sentiment: Director Timothy P. Adams bought 300,000 shares (~$1.2M at $3.99), a ~6% increase in his stake — another insider buy reinforcing management’s commitment. SEC filing: Adams purchase
Positive Sentiment: Vice-Chair Dr. Frederic H. Moll acquired 501,253 shares (~$2.0M at $3.99), increasing his holding — further insider participation. SEC filing: Moll purchase
Positive Sentiment: SS Innovations completed a private placement raising ~$18.6M (5.77M shares sold) to fund global expansion and working capital; Manipal Global Health Services led the institutional portion and insiders participated. Proceeds support U.S./EU market push while awaiting FDA review of the SSi Mantra. GlobeNewswire: Private placement
Positive Sentiment: Company released Q4 and full‑year 2025 unaudited results highlighting strong growth in SSi Mantra installations, procedures and revenue — supports the growth narrative as the firm scales device adoption. GlobeNewswire: Q4/FY2025 results
Neutral Sentiment: Quiver/market data indicates some institutional additions to SSII in recent quarters, which could provide longer‑term support but may not change near‑term volatility. QuiverQuant: Placement/ownership summary
Negative Sentiment: The private placement included a material share issuance (5.77M shares) and unregistered securities (and warrants issued to a FINRA firm), creating dilution and some liquidity/registration constraints — a common reason for downward pressure. GlobeNewswire: Private placement terms
Negative Sentiment: SSII’s growth depends on regulatory approvals (FDA 510(k) review expected mid‑2026 and CE marking efforts). Timing and outcome create execution risk that can keep the stock volatile. GlobeNewswire: Regulatory timeline

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of SS Innovations International in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of "Sell".

Read Our Latest Analysis on SS Innovations International

Institutional Trading of SS Innovations International

Hedge funds have recently added to or reduced their stakes in the stock. Inspire Investing LLC boosted its stake in SS Innovations International by 124.4% in the fourth quarter. Inspire Investing LLC now owns 82,773 shares of the company's stock valued at $470,000 after acquiring an additional 45,886 shares during the last quarter. Eversept Partners LP purchased a new position in SS Innovations International in the fourth quarter valued at approximately $428,000. Vontobel Holding Ltd. purchased a new stake in SS Innovations International in the 4th quarter worth about $116,000. Jane Street Group LLC bought a new stake in SS Innovations International in the 4th quarter valued at about $63,000. Finally, IFC & Insurance Marketing Inc. purchased a new stake in SS Innovations International during the fourth quarter valued at about $64,000.

SS Innovations International Company Profile

(Get Free Report)

AVRA Medical Robotics, Inc develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc and changed its name to AVRA Medical Robotics, Inc in November 2015. AVRA Medical Robotics, Inc was founded in 2015 and is based in Orlando, Florida.